Keywords
post-infectious irritable bowel syndrome, diarrhea, probiotics, rifaximin, diagnostics
How to Cite
Plotnikova, E. Y. (2018). Post-infectious irritable bowel syndrome. Herald of Pancreatic Club, 39(2), 61-67. https://doi.org/10.33149/vkp.2018.02.09
Abstract views: 319 PDF Downloads: 1139 PDF Downloads: 273
Abstract
Data on prevalence and etiopathogenesis of development of a post-infectious irritable bowel syndrome are provided in the article, the main manifestations of this disease and methods of their diagnostics are described. Treatment tactics is considered in details, the application of probiotics both for prevention, and for therapy of the described disease is being emphasized. Different studies on the related subject are presented.
References
1. Практические рекомендации Всемирной гастроэнтерологической организации. Синдром раздраженного кишечника: глобальные перспективы / E. Quigley, M. Fried, K. A. Gwee [et al.] – 20 апреля 2009. – Available at : http://www.worldgastroenterology
2. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome / S. P. Dunlop, N. S. Coleman, E. Blackshaw [et al.] // Clin. Gastroenterol. Hepatol. – 2005. – Vol. 3. – P. 349–357.
3. Baker D. E. Loperamide: a pharmacological review / D. E. Baker // Rev. Gastroenterol. Disord. – 2007. – Vol. 7, Suppl. 3. – S. 11–18.
4. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome / A. O. Quartero, V. Meineche-Schmidt, J. Muris [et al.] // Cochrane Database of Systematic Reviews. – 2005. – Vol. 2. – CD003460.
5. Chaudhary N. A. The irritable colon syndrome: a study of the clinical features, predisposing causes, and prognosis in 130 cases / N. A. Chaudhary, S. C. Truelove // Q. J. Med. – 1962. – Vol. 31. – P. 307–322.
6. Christen M. O. Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders / M. O. Christen // General Pharmacology: The Vascular System. – 1990. – Vol. 21, No 6. – P. 821–825.
7. Connor B. A. Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome / B. A. Connor // Clin. Infect. Dis. – 2005. – Vol. 41, Suppl. 8. – S. 577–586.
8. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA / А. K. Tuteja, N. Talley, S. S. Gelman [et al.] // Dig. Dis. Sci. – 2008. – Vol. 53. – P. 271–276.
9. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study / S. D. Parry, R. Stansfield, D. Jelley [et al.] // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 1970–1975.
10. Drossman D. A. Presidential address: gastrointestinal illness and the biopsychosocial model / D. A. Drossman // Psychosom Med. – 1998. – Vol. 60. – P. 258–267.
11. Drossman D. A. The functional gastrointestinal disorders and the Rome III process / D. A. Drossman // Rome III: the functional gastrointestinal disorders / D. A. Drossman, E. Corazziari, M. Delvaux [et al.]. – 3rd ed. – VA : Degnon Associates, 2006. – P. 1–30.
12. Drossman D. A. The functional gastrointestinal disorders and the Rome III process / D. A. Drossman // Gastroenterology. – 2006. – Vol. 130. – P. 1377–1390.
13. Drossman D. A. Treatment for bacterial overgrowth in the irritable bowel syndrome / D. A. Drossman // Ann. Intern. Med. – 2006. – Vol. 145, No 8. – P. 557–563.
14. Du Pont H. L. Postinfectious irritable bowel syndrome: clinical aspects, pathophysiology, and treatment / H. L. du Pont // Practical Gastroenterology. – 2007. – Vol. XXXI, No 9. – P. 18–24.
15. Dunlop S. P. Age-related decline in rectal mucosal lymphocytes and mast cells / S. P. Dunlop, D. Jenkins, R. C. Spiller // Eur. J. Gastroenterol. Hepatol. – 2004. – Vol. 16. – P. 1011–1015.
16. Dunlop S. P. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome / S. P. Dunlop, D. Jenkins, R. C. Spiller // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 1578–1583.
17. Dunlop S. P. Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS / S. P. Dunlop, D. Jenkins, R. C. Spiller // Gastroenterology. – 2002. – Vol. 122, Suppl. 1. – P. 60.
18. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial / M. Pimentel, S. Park, J. Mirocha [et al.] // Ann. Intern. Med. – 2006. – Vol. 145. – P. 557–563.
19. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis / A. C. Ford, N. J. Talley, M. R. Spiegel [et al.] // BMJ. – 2008. – Vol. 337. – P. 2313.
20. Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome / Т. Wittmann, A. Feher, A. Rosztoczy, J. Janosi // Orv. Hetil. – 1999. – Vol. 140, No 9. – P. 469–473.
21. Functional bowel disorders / G. F. Longstreth, W. G. Thompson, W. D. Chey [et al.] // Gastroenterology. – 2006. – Vol. 130. – P. 1480–1491.
22. Guslandi M. The clinical pharmacological profile of pinaverium bromide / M. Guslandi // Minerva Med. – 1994. – Vol. 85, No 4. – P. 179–185.
23. Gwee K. A. Increased rectal mucosal expression of interleukin 1b in recently acquired postinfectious irritable bowel syndrome / K. A. Gwee, S. M. Collins, N. W. Read // Gut. – 2003. – Vol. 52. – P. 523–526.
24. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery / J. K. Marshall, M. Thabane, A. X. Garg [et al.] // Gastroenterology. – 2006. – Vol. 131. – P. 445–450.
25. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection / M. R. Borgaonkar, D. C. Ford, J. K. Marshall [et al.] // Dig. Dis. Sci. – 2006. – Vol. 51. – P. 1026–1032.
26. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome / R. C. Spiller, D. Jenkins, J. P. Thornley [et al.] // Gut. – 2000. – Vol. 47. – P. 804–811.
27. Increased rectal mucosal expression of interleukin 1 beta in recently acquired postinfectious irritable bowel syndrome / K. A. Gwee, S. M. Collins, N. W. Read [et al.] // Gut. – 2003. – Vol. 52. – P. 523–526.
28. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario / J. K. Marshall, M. Thabane, A. X. Garg [et al.] // Aliment. Pharmacol. Ther. – 2004. – Vol. 20. – P. 1317–1322.
29. Irritable bowel syndrome in adults. Diagnosis and management of irritable bowel syndrome in primary care / National Collaborating Centre for Nursing and Supportive Care. – No. 61. – London : National Institute for Health and Clinical Excellence, 2008. – 881 p.
30. McCallum R. W. The role of calcium and calcium antagonism in motility disorders of the gastrointestinal tract / R. W. McCallum // Calcium antagonism & Gastrointestinal motility // Experta Medica. – 1989. – P. 28–31.
31. Neal K. R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients / K. R. Neal, J. Hebden, R. Spiller // BMJ. – 1997. – Vol. 314. – P. 779–782.
32. Neal K. R. Prognosis in post- infective irritable bowel syndrome: a six year follow up study / K. R. Neal, L. Barker, R. C. Spiller // Gut. – 2002. – Vol. 51. – P. 410–413.
33. Psychopathology in irritable bowel syndrome: support for a psychophysiological model / M. A. Sykes, E. В. Blanchard, J. Lackner [et al.] // J. Behav. Med. – 2003. – Vol. 26. – P. 361–372.
34. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence / A. I. Sharara, E. Aoun, H. Abdul-Baki [et al.] / Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 326–333.
35. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome / R. A. Awad, V. H. Cordova, M. Dibildox [et al.] // Acta Gastroenterol. Latinoam. – 1997. – Vol. 27, No 4. – P. 247–251.
36. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS / S. P. Dunlop, D. Jenkins, K. R. Neal, R. C. Spiller // Gastroenterology. – 2003. – Vol. 125. – P. 1651–1659.
37. Rex D. K. Add parasites to the causes of postinfectious irritable bowel syndrome / D. K. Rex // Gut. – 2012. – Vol. 61. – P. 214.
38. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome / J. Ritchie // Gut. – 1973. – Vol. 14. – P. 125–132.
39. Rogers J. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome / J. Rogers, M. M. Henry, J. J. Misiewicz // Gut. – 1989. – Vol. 30. – P. 634–641.
40. The role of psychological and biological factors in postinfective gut dysfunction / K. A. Gwee, Y. L. Leong, C. Graham [et al.] // Gut. – 1999. – Vol. 44. – P. 400–406.
41. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model / A. В. Т. Liebregts, J. M. Gschossmann [et al.] // Pain. – 2006. – Vol. 123. – P. 179–186.
42. Spence M. J. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis / M. J. Spence, R. Moss-Morris // Gut. – 2007. – Vol. 56. – P. 1066–1071.
43. Spiller R. C. Post-infectious irritable bowel syndrome / R. C. Spiller, E. Campbell // Curr. Opin. Gastroenterol. – 2006. – Vol. 22. – P. 13–17.
44. Thabane M. Systematic review and meta-analysis: the incidence and prognosis of postinfectious irritable bowel syndrome / M. Thabane, D. Т. Kottachchi, J. K. Marshall // Aliment. Pharmacol. Ther. – 2007. – Vol. 15. – P. 535–544.
45. Triantafillidis J. K. Postinfectious irritable bowel syndrome / J. K. Triantafillidis, G. Peros // Annals of Gastroenterology. – 2007. – Vol. 20, No 4. – P. 243–245.
46. Van der Veek P. P. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome / P. P. Van der Veek, M. van den Berg, Y. E. De Kroon // Am. J. Gastroenterol. – 2005. – Vol. 100. – P. 2510–2516.
47. Viera J. A. Management of irritable bowel syndrome / J. A. Viera, S. Hoag, J. Shaugnessy // Am. Fam. Physician. – 2002. – Vol. 66, No 10. – P. 1867–1875.
48. Villani A. Genetic risk factors for post-infectious IBS in the E. coli 0157: H7 outbreak in Walkerton (Canada) in 2000 / A. Villani, M. Lemire, M. Thabane // Gastroenterology. – 2008. – Vol. 134. – A122.
49. Wang L. H. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis / L. H. Wang, X. C. Fang, G. Z. Pan // Gut. – 2004. – Vol. 53. – P. 1096–1101.
50. Wesdorp I. The central role of Ca++ as mediator of gastrointestinal motility / I. Wesdorp // Calcium antagonism & Gastrointestinal motility // Experta Medica. – 1989. – P. 20–27.
51. Zanini B. Norovirus gastroenteritis may lead to post-infectious IBS / B. Zanini // Am. J. Gastroenterol. – 2012. – Vol. 10. – P. 1038.
2. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome / S. P. Dunlop, N. S. Coleman, E. Blackshaw [et al.] // Clin. Gastroenterol. Hepatol. – 2005. – Vol. 3. – P. 349–357.
3. Baker D. E. Loperamide: a pharmacological review / D. E. Baker // Rev. Gastroenterol. Disord. – 2007. – Vol. 7, Suppl. 3. – S. 11–18.
4. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome / A. O. Quartero, V. Meineche-Schmidt, J. Muris [et al.] // Cochrane Database of Systematic Reviews. – 2005. – Vol. 2. – CD003460.
5. Chaudhary N. A. The irritable colon syndrome: a study of the clinical features, predisposing causes, and prognosis in 130 cases / N. A. Chaudhary, S. C. Truelove // Q. J. Med. – 1962. – Vol. 31. – P. 307–322.
6. Christen M. O. Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders / M. O. Christen // General Pharmacology: The Vascular System. – 1990. – Vol. 21, No 6. – P. 821–825.
7. Connor B. A. Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome / B. A. Connor // Clin. Infect. Dis. – 2005. – Vol. 41, Suppl. 8. – S. 577–586.
8. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA / А. K. Tuteja, N. Talley, S. S. Gelman [et al.] // Dig. Dis. Sci. – 2008. – Vol. 53. – P. 271–276.
9. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study / S. D. Parry, R. Stansfield, D. Jelley [et al.] // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 1970–1975.
10. Drossman D. A. Presidential address: gastrointestinal illness and the biopsychosocial model / D. A. Drossman // Psychosom Med. – 1998. – Vol. 60. – P. 258–267.
11. Drossman D. A. The functional gastrointestinal disorders and the Rome III process / D. A. Drossman // Rome III: the functional gastrointestinal disorders / D. A. Drossman, E. Corazziari, M. Delvaux [et al.]. – 3rd ed. – VA : Degnon Associates, 2006. – P. 1–30.
12. Drossman D. A. The functional gastrointestinal disorders and the Rome III process / D. A. Drossman // Gastroenterology. – 2006. – Vol. 130. – P. 1377–1390.
13. Drossman D. A. Treatment for bacterial overgrowth in the irritable bowel syndrome / D. A. Drossman // Ann. Intern. Med. – 2006. – Vol. 145, No 8. – P. 557–563.
14. Du Pont H. L. Postinfectious irritable bowel syndrome: clinical aspects, pathophysiology, and treatment / H. L. du Pont // Practical Gastroenterology. – 2007. – Vol. XXXI, No 9. – P. 18–24.
15. Dunlop S. P. Age-related decline in rectal mucosal lymphocytes and mast cells / S. P. Dunlop, D. Jenkins, R. C. Spiller // Eur. J. Gastroenterol. Hepatol. – 2004. – Vol. 16. – P. 1011–1015.
16. Dunlop S. P. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome / S. P. Dunlop, D. Jenkins, R. C. Spiller // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 1578–1583.
17. Dunlop S. P. Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS / S. P. Dunlop, D. Jenkins, R. C. Spiller // Gastroenterology. – 2002. – Vol. 122, Suppl. 1. – P. 60.
18. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial / M. Pimentel, S. Park, J. Mirocha [et al.] // Ann. Intern. Med. – 2006. – Vol. 145. – P. 557–563.
19. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis / A. C. Ford, N. J. Talley, M. R. Spiegel [et al.] // BMJ. – 2008. – Vol. 337. – P. 2313.
20. Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome / Т. Wittmann, A. Feher, A. Rosztoczy, J. Janosi // Orv. Hetil. – 1999. – Vol. 140, No 9. – P. 469–473.
21. Functional bowel disorders / G. F. Longstreth, W. G. Thompson, W. D. Chey [et al.] // Gastroenterology. – 2006. – Vol. 130. – P. 1480–1491.
22. Guslandi M. The clinical pharmacological profile of pinaverium bromide / M. Guslandi // Minerva Med. – 1994. – Vol. 85, No 4. – P. 179–185.
23. Gwee K. A. Increased rectal mucosal expression of interleukin 1b in recently acquired postinfectious irritable bowel syndrome / K. A. Gwee, S. M. Collins, N. W. Read // Gut. – 2003. – Vol. 52. – P. 523–526.
24. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery / J. K. Marshall, M. Thabane, A. X. Garg [et al.] // Gastroenterology. – 2006. – Vol. 131. – P. 445–450.
25. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection / M. R. Borgaonkar, D. C. Ford, J. K. Marshall [et al.] // Dig. Dis. Sci. – 2006. – Vol. 51. – P. 1026–1032.
26. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome / R. C. Spiller, D. Jenkins, J. P. Thornley [et al.] // Gut. – 2000. – Vol. 47. – P. 804–811.
27. Increased rectal mucosal expression of interleukin 1 beta in recently acquired postinfectious irritable bowel syndrome / K. A. Gwee, S. M. Collins, N. W. Read [et al.] // Gut. – 2003. – Vol. 52. – P. 523–526.
28. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario / J. K. Marshall, M. Thabane, A. X. Garg [et al.] // Aliment. Pharmacol. Ther. – 2004. – Vol. 20. – P. 1317–1322.
29. Irritable bowel syndrome in adults. Diagnosis and management of irritable bowel syndrome in primary care / National Collaborating Centre for Nursing and Supportive Care. – No. 61. – London : National Institute for Health and Clinical Excellence, 2008. – 881 p.
30. McCallum R. W. The role of calcium and calcium antagonism in motility disorders of the gastrointestinal tract / R. W. McCallum // Calcium antagonism & Gastrointestinal motility // Experta Medica. – 1989. – P. 28–31.
31. Neal K. R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients / K. R. Neal, J. Hebden, R. Spiller // BMJ. – 1997. – Vol. 314. – P. 779–782.
32. Neal K. R. Prognosis in post- infective irritable bowel syndrome: a six year follow up study / K. R. Neal, L. Barker, R. C. Spiller // Gut. – 2002. – Vol. 51. – P. 410–413.
33. Psychopathology in irritable bowel syndrome: support for a psychophysiological model / M. A. Sykes, E. В. Blanchard, J. Lackner [et al.] // J. Behav. Med. – 2003. – Vol. 26. – P. 361–372.
34. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence / A. I. Sharara, E. Aoun, H. Abdul-Baki [et al.] / Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 326–333.
35. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome / R. A. Awad, V. H. Cordova, M. Dibildox [et al.] // Acta Gastroenterol. Latinoam. – 1997. – Vol. 27, No 4. – P. 247–251.
36. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS / S. P. Dunlop, D. Jenkins, K. R. Neal, R. C. Spiller // Gastroenterology. – 2003. – Vol. 125. – P. 1651–1659.
37. Rex D. K. Add parasites to the causes of postinfectious irritable bowel syndrome / D. K. Rex // Gut. – 2012. – Vol. 61. – P. 214.
38. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome / J. Ritchie // Gut. – 1973. – Vol. 14. – P. 125–132.
39. Rogers J. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome / J. Rogers, M. M. Henry, J. J. Misiewicz // Gut. – 1989. – Vol. 30. – P. 634–641.
40. The role of psychological and biological factors in postinfective gut dysfunction / K. A. Gwee, Y. L. Leong, C. Graham [et al.] // Gut. – 1999. – Vol. 44. – P. 400–406.
41. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model / A. В. Т. Liebregts, J. M. Gschossmann [et al.] // Pain. – 2006. – Vol. 123. – P. 179–186.
42. Spence M. J. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis / M. J. Spence, R. Moss-Morris // Gut. – 2007. – Vol. 56. – P. 1066–1071.
43. Spiller R. C. Post-infectious irritable bowel syndrome / R. C. Spiller, E. Campbell // Curr. Opin. Gastroenterol. – 2006. – Vol. 22. – P. 13–17.
44. Thabane M. Systematic review and meta-analysis: the incidence and prognosis of postinfectious irritable bowel syndrome / M. Thabane, D. Т. Kottachchi, J. K. Marshall // Aliment. Pharmacol. Ther. – 2007. – Vol. 15. – P. 535–544.
45. Triantafillidis J. K. Postinfectious irritable bowel syndrome / J. K. Triantafillidis, G. Peros // Annals of Gastroenterology. – 2007. – Vol. 20, No 4. – P. 243–245.
46. Van der Veek P. P. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome / P. P. Van der Veek, M. van den Berg, Y. E. De Kroon // Am. J. Gastroenterol. – 2005. – Vol. 100. – P. 2510–2516.
47. Viera J. A. Management of irritable bowel syndrome / J. A. Viera, S. Hoag, J. Shaugnessy // Am. Fam. Physician. – 2002. – Vol. 66, No 10. – P. 1867–1875.
48. Villani A. Genetic risk factors for post-infectious IBS in the E. coli 0157: H7 outbreak in Walkerton (Canada) in 2000 / A. Villani, M. Lemire, M. Thabane // Gastroenterology. – 2008. – Vol. 134. – A122.
49. Wang L. H. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis / L. H. Wang, X. C. Fang, G. Z. Pan // Gut. – 2004. – Vol. 53. – P. 1096–1101.
50. Wesdorp I. The central role of Ca++ as mediator of gastrointestinal motility / I. Wesdorp // Calcium antagonism & Gastrointestinal motility // Experta Medica. – 1989. – P. 20–27.
51. Zanini B. Norovirus gastroenteritis may lead to post-infectious IBS / B. Zanini // Am. J. Gastroenterol. – 2012. – Vol. 10. – P. 1038.